EIF2AK3 and colorectal carcinoma: A recent study by Shi et al. [233] also revealed that not only PERK, but also ATF4 activity was significantly elevated in CRC cells demonstrating heightened resistance to 5-FU, a chemotherapeutic for the first-line treatment of patients with advanced CRC.